Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02150525 · ClinicalTrials.gov registry record · Phase 2
Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors
A Phase 2 study of Breast Cancer Stage II and Breast Cancer Stage III, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT02150525 is a Phase 2 study of Breast Cancer Stage II and Breast Cancer Stage III that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 52 participants, below the 180-participant average among 22 other Breast Cancer Stage II trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02150525, a Phase 2 study of Breast Cancer Stage II and Breast Cancer Stage III, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized double-blind clinical trial studied the effect of oral omega-3 fatty acid on atrophic vaginitis in postmenopausal breast cancer survivors (N=52). Omega-3 fatty acid may reduce inflammation and improve vaginal symptoms in postmenopausal breast cancer survivors.
Conditions Studied
Interventions
- OTHER placebo
- DIETARY_SUPPLEMENT omega-3 fatty acid
- BEHAVIORAL Questionnaire administration
Study Locations (1)
Ohio
- The Ohio State University Medical Center, Comprehensive Breast Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2010-08 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02150525
The ClinicalTrials.gov registry entry for NCT02150525 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 180-participant average among 22 other Breast Cancer Stage II trials with a reported enrollment target (71% lower). The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Breast Cancer Stage II appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT02150525 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT02150525 about?
NCT02150525 is a clinical study titled "Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors". This randomized double-blind clinical trial studied the effect of oral omega-3 fatty acid on atrophic vaginitis in postmenopausal breast cancer survivors (N=52). Omega-3 fatty acid may reduce inflammation and improve vaginal symptoms in postmenopausal breast cancer survivors.
What is the current status of trial NCT02150525?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2010-08. Estimated completion is 2013-01.
What conditions does trial NCT02150525 study?
This clinical trial studies the following conditions: Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage I, Ductal Breast Carcinoma in Situ.
What interventions are being tested in trial NCT02150525?
The interventions under investigation include: placebo (OTHER), omega-3 fatty acid (DIETARY_SUPPLEMENT), Questionnaire administration (BEHAVIORAL).
Who is sponsoring clinical trial NCT02150525?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02150525 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer Stage II
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
RECRUITING · Phase 2
-
Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
RECRUITING · Phase 2
-
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
RECRUITING · Phase 2
-
Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)
RECRUITING · Phase 2
-
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.